nVerses Capital’s Terns Pharmaceuticals TERN Stock Holding History

nVerses Capital’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,700	Closed	-$47.5K	–	803
2024 Q3	$47.5K	Buy	+5,700	New	+$46.9K	0.02%	650

Other funds holding TERN

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

nVerses Capital's TERN Position: Q4 2024 in Review

nVerses Capital sold out of Terns Pharmaceuticals (TERN) in Q4 2024, closing a stake of 5,700 shares — an estimated $47.5K sold.

nVerses Capital first reported a position in TERN in Q3 2024 and held it in 1 quarter. The position peaked at $47.5K in Q3 2024. 157 funds tracked by Wall St. Rank hold TERN as of Q4 2024.

nVerses Capital reported no remaining Terns Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 5,700 Terns Pharmaceuticals shares in Q4 2024, an estimated $47.5K.
nVerses Capital first reported a position in Terns Pharmaceuticals in Q3 2024 and held it in 1 quarter.
nVerses Capital's Terns Pharmaceuticals position peaked at $47.5K in Q3 2024.
157 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.